Friday, June 26, 2015 11:09:59 AM
The only credible argument would be that this "licensed IP" is actually possibly linked to the current pipeline products in a way that they see huge potential.
But if so, why not keep it as part of RGBP IP instead of giving "exclusive" rights to Zander? As I say, the only legitimate move here that I can even imagine is that this IP needs validation in animal testing first before RGBP could use in human application and having Zander do the testing keeps it in house, but with RGBP hopefully making progress on various fronts, I don't know why they wouldn't keep this IP as something for RGBP to develop and build on its own momentum.
Multiplying psuedo companies to spin shares all under the name and fist of one person, Koos, does not build investor confidence, especially with the licensing a cover for Koos to issue more shares.
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM